Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006481 | 1.00 | THRA (0.44) | THRATHRBPOLBALDH1A1MAPT | |
| SCHEMBL1007703 | 0.88 | GAA (0.52) | ALDH1A1MAPTSMN1; SMN2CNR1CNR2 | |
| SCHEMBL1007701 | 0.88 | GAA (0.52) | ALDH1A1MAPTSMN1; SMN2CNR1CNR2 | |
| SCHEMBL1006910 | 0.86 | HCRTR2 (0.45) | HCRTR2HDAC1GAA | |
| SCHEMBL1006912 | 0.86 | HCRTR2 (0.45) | HCRTR2HDAC1GAA | |
| SCHEMBL1008000 | 0.84 | ITGB3 (0.42) | SMN1; SMN2CNR1CNR2HDAC1MMEL1 | |
| SCHEMBL1008001 | 0.84 | ITGB3 (0.42) | SMN1; SMN2CNR1CNR2HDAC1MMEL1 | |
| SCHEMBL4296581 | 0.84 | HDAC1 (0.54) | ALDH1A1HDAC1GAA | |
| SCHEMBL1009242 | 0.84 | HDAC1 (0.54) | ALDH1A1HDAC1GAA | |
| SCHEMBL1005796 | 0.84 | HDAC1 (0.54) | ALDH1A1HDAC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268606-B1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | claimed |
| US-8344027-B2 | 4-dimethylaminobutyric acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | ANDJELKOVIC MIRJANA (CH) | 2012-11-15 | — | — | US | claimed |
| EP-2268606-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | claimed |
| WO-2009132978-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | claimed |
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-10-29 | — | — | US | claimed |
| EP-2268606-B1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8344027-B2 | 4-dimethylaminobutyric acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | ANDJELKOVIC MIRJANA (CH) | 2012-11-15 | — | — | US | disclosed |
| EP-2268606-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009132978-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | THRA 1447/4885THRB 517/4885POLB 816/4885 |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | THRA 1447/4885THRB 517/4885POLB 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.